146 related articles for article (PubMed ID: 30877678)
21. Prospects for the prevention of meningococcal disease: special reference to group B.
Frasch CE
Vaccine; 1987 Mar; 5(1):3-4. PubMed ID: 3107234
[TBL] [Abstract][Full Text] [Related]
22. [Clinico-immunological characteristics in children given meningococcal group A polysaccharide vaccine developed at the G. N. Gabrichevskĭ Moscow Research Institute of Epidemiology and Microbiology].
Skirda TA; Golovina LI; Mishina AI; Chernyshova TF; Savchenko LG; Chernyshova MS
Pediatriia; 1992; (2):55-9. PubMed ID: 1513635
[No Abstract] [Full Text] [Related]
23. Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitidis serogroup C.
Westerink MA; Campagnari AA; Wirth MA; Apicella MA
Infect Immun; 1988 May; 56(5):1120-7. PubMed ID: 3128477
[TBL] [Abstract][Full Text] [Related]
24. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.
Rennels M; King J; Ryall R; Papa T; Froeschle J
Pediatr Infect Dis J; 2004 May; 23(5):429-35. PubMed ID: 15131466
[TBL] [Abstract][Full Text] [Related]
25. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
[TBL] [Abstract][Full Text] [Related]
26. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
Granoff DM; Gupta RK; Belshe RB; Anderson EL
J Infect Dis; 1998 Sep; 178(3):870-4. PubMed ID: 9728562
[TBL] [Abstract][Full Text] [Related]
27. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
28. Fighting Neisseria meningitidis: past and current vaccination strategies.
Piccini G; Torelli A; Gianchecchi E; Piccirella S; Montomoli E
Expert Rev Vaccines; 2016 Nov; 15(11):1393-1407. PubMed ID: 27158988
[TBL] [Abstract][Full Text] [Related]
29. Development and characterization of anti-idiotype based peptide and DNA vaccines which mimic the capsular polysaccharide of Neisseria meningitidis serogroup C.
Westerink MA; Smithson SL; Hutchins WA; Widera G
Int Rev Immunol; 2001; 20(2):251-61. PubMed ID: 11878768
[TBL] [Abstract][Full Text] [Related]
30. Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135.
Lal G; Balmer P; Joseph H; Dawson M; Borrow R
Clin Diagn Lab Immunol; 2004 Mar; 11(2):272-9. PubMed ID: 15013975
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes.
Shin JS; Lin JS; Anderson PW; Insel RA; Nahm MH
Infect Immun; 2001 May; 69(5):3335-42. PubMed ID: 11292756
[TBL] [Abstract][Full Text] [Related]
32. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
33. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
[TBL] [Abstract][Full Text] [Related]
34. Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.
Drogari-Apiranthitou M; Fijen CA; Van De Beek D; Hensen EF; Dankert J; Kuijper EJ
Clin Exp Immunol; 2000 Feb; 119(2):311-6. PubMed ID: 10632668
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA.
Phugare S; Kale S; Sharma P; Kumar Goel S; Gairola S; Jadhav SS
Vaccine; 2020 Nov; 38(49):7815-7824. PubMed ID: 33164804
[TBL] [Abstract][Full Text] [Related]
36. Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005.
Alonso JM; Gilmet G; Rouzic EM; Nassif X; Plotkin SA; Ramsay M; Siegrist CA; Stephens DS; Teyssou R; Vogel U
Vaccine; 2007 May; 25(21):4125-9. PubMed ID: 17449149
[TBL] [Abstract][Full Text] [Related]
37. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy.
Occhionero M; Usai G; Di Martino M; Le Moli S; Stroffolini T; Mastrantonio P
Allergol Immunopathol (Madr); 1991; 19(1):39-41. PubMed ID: 1950941
[TBL] [Abstract][Full Text] [Related]
38. Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease.
Moe GR; Tan S; Granoff DM
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):209-26. PubMed ID: 10575132
[TBL] [Abstract][Full Text] [Related]
39. Production of polyclonal and monoclonal antibodies against group A, B, and C capsular polysaccharides of Neisseria meningitidis and preparation of latex reagents.
Nato F; Mazie JC; Fournier JM; Slizewicz B; Sagot N; Guibourdenche M; Postic D; Riou JY
J Clin Microbiol; 1991 Jul; 29(7):1447-52. PubMed ID: 1909346
[TBL] [Abstract][Full Text] [Related]
40. Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.
Coquillat D; Bruge J; Danve B; Latour M; Hurpin C; Schulz D; Durbec P; Rougon G
Infect Immun; 2001 Nov; 69(11):7130-9. PubMed ID: 11598089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
